Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The phase 3 ATTAIN-1 trial compared results for 3127 adult participants with obesity, or who were overweight with a weight-related medical problem, and who did not have diabetes
The peptide, typically administered as a nasal spray, has shown the most promise in humans for treating neurological conditions, particularly ischemic stroke, but there is no evidence for general cognitive enhancement
Its effects on inflammatory markers appear similar to other agents in the class, though with potentially less weight loss benefit than newer agents like semaglutide
There are only two GLP-1 agonists that are TGA approved for weight loss, semaglutide ( Wegovy brand) and liraglutide ( Saxenda )
Risks of Extended GLP-1 Use The risks of extended GLP-1 use are still being studied, and while many people use them safely, potential concerns include: Digestive issues Some patients may experience ongoing nausea, constipation, or discomfort
Together, these changes position menopause as a critical inflection point in the trajectory of metabolic health
US$ 29.27
US$ 29.78
US$ 23.31
US$ 28.69
US$ 24.40
US$ 24.61
US$ 25.80
US$ 24.90
US$ 26.34
US$ 22.02
